業績公告
即時報告
8-K
2026-08-10
Village Farms第二季大麻收入創新高 連續五季錄正盈利
AI 繁中摘要
📊 8-K | Village Farms International（NASDAQ: VFF）公佈2026年第二季業績：大麻收入創新高，連續第五季錄得正盈利
綜合控股公司Village Farms International公佈截至2026年6月30日止第二季度業績，受惠於大麻業務收入創新高及年初至今收成產量理想，集團整體表現強勁。
📌 財務亮點（第二季，美元）
• 綜合淨銷售額按季增27%、按年增7%，達6,400萬美元。
• 淨收入錄得710萬美元，每股攤薄盈利0.06美元；經營現金流890萬美元。
• 大麻分部淨銷售5,350萬美元，按年增5%；毛利率由42%顯著擴闊至51%。
• 大麻分部來自持續經營業務的經調整EBITDA創季度新高，達1,530萬美元，相當於該分部銷售額28.5%，按年增16%。
• 國際出口銷售創新高，達2,090萬美元，按年增74%、按季增43%。
• 集團季末持有現金7,300萬美元。
📌 業務及營運重點
- 加拿大Delta設施於2026年上半年錄得創紀錄收成產量，生產成本進一步下降；Delta 2擴建項目首期已收成，預期2026年下半年貢獻約15公噸乾花，並於2027年中前達到每年40公噸全面產能。
- 集團旗下品牌首次在加拿大所有主要產品類別均晉身全國市場份額前十，尤其於vapes及注入式預卷煙類別持續增長。
- 荷蘭Groningen第二期設施已於季內開始種植，預計2027年初全面投產，屆時荷蘭年產能將增至約10公噸。
- 集團於6月完成註冊直接發售，向兩家美國機構投資者發行750萬股，集資約1,500萬美元（未扣除費用）。
- 於2026年「商業大麻獎」中獲頒「年度生產商」獎項。
📌 管理層展望
行政總裁Michael DeGiglio表示，集團連續第五季錄得正淨收入及每股盈利，反映全球大麻平台持續擴張的成果。管理層強調，即使不計入去年同期一次性430萬美元供應商和解收益，經調整EBITDA仍錄得可觀按年增長。集團預期荷蘭業務將於明年第一季末達至全面產能，Delta 2擴建亦將於2027年中達至全面產能，為長期有機增長提供清晰路徑。對於美國市場，管理層表明會保持審慎及耐心，繼續評估全球有機增長及併購機會，同時以盈利能力及股東長期價值為優先考慮。
📈 對投資者的潛在影響
- 大麻分部盈利能力持續改善，毛利率擴闊九個百分點，顯示營運槓桿效應正在浮現。
- 國際出口業務高速增長，加上荷蘭及加拿大產能擴充，有助分散地域風險及降低對單一市場的依賴。
- 現金流穩定及資本開支接近完成，財務狀況相對穩健，惟上半年經營現金流受營運資金變動影響錄得負數，值得留意。
- 集團股東應佔淨收入為710萬美元
展開英文正文
EX-99.1 2 vff-ex99_1.htm EX-99.1 EX-99.1 Village Farms Reports Q2 2026 Results Driven by Record Cannabis Revenues and Year-to-Date Harvest Yields •Consolidated Net Sales Increased 27% Sequentially and 7% Year-over-Year to $64 Million •Net Income of $7.1 Million or $0.06 Per Share; Operating Cash Flow of $8.9 Million •Company Achieves Record Harvest Yields in Delta Facilities in 1H’26 with Improved Cost of Production •Record Export Sales of $20.9 Million Grew 74% YoY and 43% Sequentially •Record Q2 Cannabis Segment Adjusted EBITDA from Continuing Ops of $15.3 Million or 29% of Sales •Netherlands and Canadian Expansion CapEx Nearly Complete; Closes Q2 with $73 Million in Cash VANCOUVER, British Columbia, August 10, 2026 – Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today reported financial results for its second quarter ended June 30, 2026. All figures are in U.S. dollars unless otherwise indicated. Management Commentary President and Chief Executive Officer Michael DeGiglio commented, “Our second quarter results continue to demonstrate the strength of our expanding global cannabis platform, driven by record cannabis revenues of $53.5 million as we continued to grow in target markets and product categories around the world. We delivered our fifth consecutive quarter of positive net income and EPS since we privatized our legacy produce business last year, and important to note that when excluding the one-time $4.3 million vendor settlement received in the second quarter of last year, consolidated adjusted EBITDA increased meaningfully year-over-year to $15.4 million with record Q2 cannabis performance.” “We’re having a record year of production in our Delta, British Columbia facilities even without including the first harvest we completed in our Delta 2 greenhouse expansion, and record yields combined with greater operating efficiencies have resulted in a lower cost of production. Favorable sales mix also helped drive nine percentage points of cannabis gross margin expansion which translated to strong operating leverage with adjusted EBITDA and net income both meaningfully outpacing total sales growth.” “We’re continuing to gain traction with our efforts to grow market share in convenience product categories in Canada, where for the first time our brands achieved top 10 market share in all major categories with continued growth in vapes and infused pre-rolls. It was also another record quarter of international export sales, which grew 74% year-over-year and 43% sequentially as we continue to benefit from our competitive advantage with the world’s largest EU-GMP certified cannabis facility. We have a growing share of Europe’s total addressable cannabis market with leading share and distribution in Germany, and we continue to expect that we’ll enter multiple new European jurisdictions later this year.” “We’re entering the second half of the year in a position of strength, and we’re positioned for continued profitable growth regardless of our entry point and timing into the U.S. market with a global cannabis enterprise that is now approaching 50% of revenues from growing international markets. Our Netherlands operations are expected to ramp to full production capacity by the end of Q1 next year, and our Delta 2 expansion in Canada remains on track to reach its full 40 tonne production run rate by mid-2027, both of which provide us with a clear path for continued long-term organic growth.” “We closed the second quarter with $73 million in cash, and we continue to expect that we’ll grow our cash balance from positive operating cash flow through the remainder of the year. We’re continuing to evaluate additional organic and acquisitive growth investments around the world, but remain prudent and patient with respect to valuation with a focus on profitability and long-term value creation for our shareholders.” Second Quarter 2026 Financial Highlights (All comparable periods are for the second quarter of 2025 unless otherwise stated) Cannabis Operations •Net sales increased 5% to $53.5 million, from $50.8 million in the prior year period; •Gross margin increased to 51% from 42% in the prior year period; •Net income improved to $8.6 million from $7.1 million, an increase of 21% year-over-year; •Adjusted EBITDA from continuing operations increased 16% to $15.3 million or 28.5% of sales, compared to $13.1 million or 25.8% of sales in the prior year period; and •Cash flow from operations was $8.9 million. Strategic Growth and Operational Highlights •Maintained the Company’s top five overall market share position in the Canadian market and expanded its market share in vapes and infused pre-rolls, now positioning the Company’s brand portfolio among the top 10 nationally in all major product categories1. •Achieved record production from the Company’s Delta, British Columbia facilities during 1H’26. Increased yields and greater operating efficiencies led to lower production costs during Q2, and favorable sales mix helped drive nine percentage points of year-over-year cannabis segment gross margin expansion. •International export sales increased 74% year-over-year and 43% sequentially to a record high of $20.9 million. The Company believes it remains the largest exporter of medical cannabis to Europe with a leading market share position in Germany. •The Company commenced cultivation at its Phase II facility in Groningen, Netherlands during Q2. The Groningen facility will bring the Company’s maximum annualized production capacity in the Netherlands to approximately 10 metric tonnes and is expected to ramp to full production into early 2027. •During Q2 the Company harvested its first crop from the first half of its Delta 2 greenhouse expansion, and announced that it is accelerating technology upgrades quicker than previously anticipated due to increasing global demand. The Delta 2 expansion is expected to yield approximately 15 metric tonnes of dried, trimmed flower during the second half of 2026. The Delta 2 expansion is expected to ramp to its full production capacity of 40 metric tonnes by mid-2027, bringing total production capacity from the Delta campus to approximately 160 metric tonnes of dried, trimmed flower annually. Corporate and Other •On May 27, 2026 the Company was awarded “Producer of the Year” at the 2026 Business of Cannabis Awards in London. The award recognizes excellence and innovation in cannabis cultivation practices, techniques, and product quality, and celebrates cultivators who have demonstrated exceptional skill, dedication, and expertise in producing high-quality cannabis while adhering to best practices in sustainability, compliance, and safety. •On June 5, 2026 the Company entered into securities purchase agreements for the purchase and sale of 7,500,000 common shares of the Company in a registered direct offering subscribed to by two U.S. institutional investors. The offering yielded gross proceeds of approximately $15 million before deducting placement agent fees and other expenses. 1.Based on estimated retail sales from HiFyre, other third parties and provincial boards. Conference Call Village Farms’ management team will host a conference call to discuss its second quarter 2026 financial results today, Monday, August 10, 2026, at 8:30 a.m. ET. Participants can access the conference call via a webcast at Village Farms Second Quarter 2026 Conference Call Webcast or on the Company website at Village Farms - Events. Participants wanting to access the conference call by telephone must register in advance at Village Farms Second Quarter 2026 Conference Call Registration to receive telephone dial-in information. The live question and answer session will be limited to analysts; however, others are invited to submit questions ahead of the conference call via email at [email protected]. Management will address questions received via email during the question-and-answer session as time permits. About Village Farms International, Inc. Village Farms is a global leader in cannabis, plant-based consumer packaged goods, and sustainable innovation. With a legacy built on decades of Controlled Environment Agriculture expertise and Dutch farming practices, today the Company is one of the world’s largest and most profitable cannabis operators with an asset portfolio that spans over 7 million square feet of advanced greenhouse and indoor cultivation assets. In Canada, Village Farms operates the world’s largest EU-GMP certified cannabis facility at its production campus in Delta, British Columbia, and exports products to international medical markets. The Company is also a market share leader in dried flower formats and produces and distributes some of the country’s highest quality and best-selling strains, including its flagship Pure Sunfarms Pink Kush, one of the most widely consumed strains on the planet. Village Farms’ Canadian brand portfolio includes Pure Sunfarms, Fraser Valley Weed Co., Soar, Super Toast, Pure Laine, Tam Tams and Promenade. In the Netherlands, the Company is one of only ten licensed operators in the country’s regulated cannabis program, and in the United States its CBDistillery brand is one of the country’s premier cannabinoid wellness platforms, and it also holds equity interests in cannabis businesses in Australia and Germany. Beyond cannabis, the Company holds an equity interest in Verdexa Holdings, a private venture pursuing strategic acquisitions to build a premier branded food platform, and its Clean Energy division transforms landfill gas into renewable natural gas and receives royalties on all revenues generated. Contact Information Sam Gibbons Senior Vice President, Corporate Affairs Phone: (407) 495-5067 Email: [email protected] Cannabis Performance Summary (thousands except % metrics) Three Months Ended June 30, 2026 2025 USD $ USD $ Change Total Net Sales $ 53,523 $ 50,842 5% Total Cost of Sales $ 26,246 $ 29,502 -11% Gross Profit $ 27,277 $ 21,340 28% Gross Margin % 51 % 42 % 21% SG&A $ 15,203 $ 11,606 31% Net income $ 8,603 $ 7,098 21% Adjusted EBITDA from Continuing Operations (1) $ 15,273 $ 13,123 16% Adjusted EBITDA from Continuing Operations Margin (2) 29 % 26 % 12% Cash flow from Operations $ 8,996 $ 19,172 -53% (millions except % metrics) Six Months Ended June 30, 2026 2025 USD $ USD $ Change Total Net Sales $ 103,267 $ 90,069 15% Total Cost of Sales $ 54,682 $ 53,460 2% Gross Profit $ 48,585 $ 36,609 33% Gross Margin % 47 % 41 % 15% SG&A $ 30,023 $ 23,342 29% Net income $ 13,383 $ 9,946 35% Adjusted EBITDA from Continuing Operations (1) $ 25,479 $ 20,012 27% Adjusted EBITDA from Continuing Operations Margin (1) 25 % 22 % 14% Cash flow from Operations $ (2,814 ) $ 22,058 NM (1)Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect our business performance. Adjusted EBITDA from continuing operations includes the Company’s 86.6% interest in Rose LifeScience. For a reconciliation of Adjusted EBITDA from continuing operations to net income (the most comparable measure under GAAP), see “Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)” below. (2)Adjusted EBITDA from Continuing Operations Margin is calculated as Adjusted EBITDA from continuing operations (which is a non-GAAP measure) divided by Total Net Sales. See footnote (1) above for more information regarding Adjusted EBITDA from continuing operations. Composition of Sales by Channel Three Months Ended June 30, Classification 2026 2025 Cannabis: Canadian Branded (1) $ 23,017 $ 24,962 Canadian Non-Branded 3,040 7,077 International Exports 20,897 11,980 U.S. Cannabis 3,224 3,841 Netherlands Branded 3,345 2,483 Other — 499 Total Cannabis 53,523 50,842 Other Produce 10,185 8,574 Clean Energy 269 483 Total Revenue $ 63,977 $ 59,899 (1)Canadian Branded revenues are shown net of excise tax on products. Excise tax on products was $14,909 and $14,812 for the three months ended June 30, 2026 and 2025, respectively. Six Months Ended June 30, Classification 2026 2025 Cannabis: Canadian Branded (1) $ 46,865 $ 47,713 Canadian Non-Branded 8,417 13,367 International Exports 35,478 17,368 U.S. Cannabis 6,357 7,745 Netherlands Branded 6,008 2,969 Other 142 907 Total Cannabis 103,267 90,069 Other Produce 10,293 8,601 Clean Energy 655 909 Total Revenue $ 114,215 $ 99,579 (1)Canadian Branded revenues are shown net of excise tax on products. Excise tax on products was $30,812 and $28,759 for the six months ended June 30, 2026 and 2025, respectively. Presentation of Financial Results The Company’s financial statements for the three and six months ended June 30, 2026, as well as the comparative period for 2025, have been prepared and presented under United States Generally Accepted Accounting Principles (“GAAP”). RESULTS OF OPERATIONS (In thousands of U.S. dollars, except per share amounts, and unless otherwise noted) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Sales $ 63,977 $ 59,899 $ 114,215 $ 99,579 Cost of sales (34,004 ) (37,557 ) (63,256 ) (63,057 ) Gross profit 29,973 22,342 50,959 36,522 Selling, general and administrative expenses (18,811 ) (15,411 ) (34,753 ) (30,030 ) Interest expense (477 ) (814 ) (1,000 ) (1,516 ) Interest income 343 109 951 184 Foreign exchange (loss) gain (597 ) 1,792 (1,145 ) 1,708 Other (loss) income 24 4,430 (159 ) 4,451 Income (loss) before taxes and equity method investment income 10,455 12,448 14,853 11,319 Provision for income taxes (3,262 ) (2,503 ) (4,930 ) (3,486 ) Equity method investment income, net of tax — — — — Income (loss) from continuing operations 7,193 9,945 9,923 7,833 (Loss) Income from discontinued operations, net of tax — 16,294 — 11,291 Income (loss) including non-controlling interests 7,193 26,239 9,923 19,124 Less: net (income) loss attributable to non-controlling interests, net of tax (48 ) 258 139 670 Net income (loss) attributable to Village Farms International, Inc. shareholders $ 7,145 $ 26,497 $ 10,062 $ 19,794 Adjusted EBITDA from continuing operations (1) $ 15,411 $ 17,111 $ 25,311 $ 20,560 Basic income (loss) per share attributable to Village Farms International, Inc. shareholders from: Continuing operations $ 0.06 $ 0.09 $ 0.09 $ 0.08 Discontinued operations - 0.15 - 0.10 Basic income (loss) per share attributable to Village Farms International, Inc. shareholders $ 0.06 $ 0.24 $ 0.09 $ 0.18 Diluted income (loss) per share attributable to Village Farms International, Inc. shareholders from: Continuing operations $ 0.06 $ 0.10 $ 0.08 $ 0.08 Discontinued operations - 0.14 - 0.10 Diluted income (loss) per share attributable to Village Farms International, Inc. shareholders $ 0.06 $ 0.24 $ 0.08 $ 0.18 (1)Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect our business performance. Adjusted EBITDA from continuing operations includes the Company’s 86.6% interest in Rose LifeScience. For a reconciliation of Adjusted EBITDA from continuing operations to net income (the most comparable measure under GAAP), see “Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)” below. We caution that our results of operations for the three and six months ended June 30, 2026 and 2025 may not be indicative of our future performance. SEGMENTED RESULTS OF OPERATIONS (In thousands of U.S. dollars, except per share amounts, and unless otherwise noted) For The Three Months Ended June 30, 2026 Cannabis Other Corporate Total Sales $ 53,523 $ 10,454 $ — $ 63,977 Cost of sales (26,246 ) (7,758 ) — (34,004 ) Selling, general and administrative expenses (15,203 ) (712 ) (2,896 ) (18,811 ) Other expense, net (207 ) (204 ) (296 ) (707 ) Income (loss) before taxes and equity method investment income 11,867 1,780 (3,192 ) 10,455 Provision for income taxes (3,216 ) (46 ) — (3,262 ) Equity method investment income, net of tax — — — — Income (loss) including non-controlling interests 8,651 1,734 (3,192 ) 7,193 Less: net loss attributable to non-controlling interests, net of tax (48 ) — — (48 ) Net income (loss) $ 8,603 $ 1,734 $ (3,192 ) $ 7,145 Adjusted EBITDA from Continuing Operations(1) $ 15,273 $ 2,776 $ (2,638 ) $ 15,411 Basic income (loss) per share $ 0.08 $ 0.01 $ (0.03 ) $ 0.06 Diluted income (loss) per share $ 0.08 $ 0.01 $ (0.03 ) $ 0.06 For The Three Months Ended June 30, 2025 Cannabis Other Corporate Total Sales $ 50,842 $ 9,057 $ — $ 59,899 Cost of sales (29,502 ) (8,055 ) — (37,557 ) Selling, general and administrative expenses (11,606 ) (843 ) (2,962 ) (15,411 ) Other (expense) income, net (507 ) 4,471 1,553 5,517 Income (loss) before taxes and equity method investment income 9,227 4,630 (1,409 ) 12,448 Provision for income taxes (2,387 ) (135 ) 19 (2,503 ) Equity method investment income, net of tax — — — — Income (loss) from continuing operations 6,840 4,495 (1,390 ) 9,945 Income from discontinued operations net of tax — 16,294 — 16,294 Income (loss) including non-controlling interests 6,840 20,789 (1,390 ) 26,239 Less: net loss attributable to non-controlling interests, net of tax 258 — — 258 Net income (loss) $ 7,098 $ 20,789 $ (1,390 ) $ 26,497 Adjusted EBITDA from Continuing Operations(1) $ 13,123 $ 6,833 $ (2,845 ) $ 17,111 Basic income (loss) per share from continuing operations $ 0.06 $ 0.04 $ (0.01 ) $ 0.09 Basic income per share from discontinued operations $ - $ 0.15 $ - $ 0.15 Basic income (loss) per share $ 0.06 $ 0.19 $ (0.01 ) $ 0.24 Diluted income (loss) per share from continuing operations $ 0.06 $ 0.05 $ (0.01 ) $ 0.10 Diluted income per share from discontinued operations $ - $ 0.14 $ - $ 0.14 Diluted income (loss) per share $ 0.06 $ 0.19 $ (0.01 ) $ 0.24 For The Six Months Ended June 30, 2026 Cannabis Other Corporate Total Sales $ 103,267 $ 10,948 $ — $ 114,215 Cost of sales (54,682 ) (8,574 ) — (63,256 ) Selling, general and administrative expenses (30,023 ) (1,224 ) (3,506 ) (34,753 ) Other expense, net (517 ) (426 ) (410 ) (1,353 ) Income (loss) before taxes and equity method investment income 18,045 724 (3,916 ) 14,853 Provision for income taxes (4,801 ) (129 ) — (4,930 ) Equity method investment income, net of tax — — — — Income (loss) from continuing operations 13,244 595 (3,916 ) 9,923 Less: net loss attributable to non-controlling interests, net of tax 139 — — 139 Net income (loss) $ 13,383 $ 595 $ (3,916 ) $ 10,062 Adjusted EBITDA from continuing operations (1) $ 25,479 $ 2,753 $ (2,921 ) $ 25,311 Basic income (loss) per share from continuing operations $ 0.12 $ - $ (0.03 ) $ 0.09 Basic income per share from discontinued operations $ - $ - $ - $ - Basic income (loss) per share $ 0.12 $ - $ (0.03 ) $ 0.09 Diluted income (loss) per share from continuing operations $ 0.11 $ - $ (0.03 ) $ 0.08 Diluted income per share from discontinued operations $ - $ - $ - $ - Diluted income (loss) per share $ 0.11 $ - $ (0.03 ) $ 0.08 For The Six Months Ended June 30, 2025 Cannabis Other Corporate Total Sales $ 90,069 $ 9,510 $ — $ 99,579 Cost of sales (53,460 ) (9,597 ) — (63,057 ) Selling, general and administrative expenses (23,342 ) (1,586 ) (5,102 ) (30,030 ) Other expense (income), net (709 ) 3,943 1,593 4,827 (Loss) income before taxes and equity method investment income 12,558 2,270 (3,509 ) 11,319 Provision for income taxes (3,282 ) (204 ) — (3,486 ) Equity method investment income, net of tax — — — — Income (loss) from continuing operations 9,276 2,066 (3,509 ) 7,833 Income from discontinued operations net of tax — 11,291 — 11,291 Income (loss) including non-controlling interests 9,276 13,357 (3,509 ) 19,124 Less: net loss attributable to non-controlling interests, net of tax 670 — — 670 Net income (loss) $ 9,946 $ 13,357 $ (3,509 ) $ 19,794 Adjusted EBITDA from continuing operations (1) $ 20,012 $ 5,404 $ (4,856 ) $ 20,560 Basic (loss) income per share from continuing operations $ 0.09 $ 0.02 $ (0.03 ) $ 0.08 Basic loss per share from discontinued operations $ - $ 0.10 $ - $ 0.10 Basic (loss) income per share $ 0.09 $ 0.12 $ (0.03 ) $ 0.18 Diluted (loss) income per share from continuing operations $ 0.09 $ 0.02 $ (0.03 ) $ 0.08 Diluted loss per share from discontinued operations $ - $ 0.10 $ - $ 0.10 Diluted (loss) income per share $ 0.09 $ 0.12 $ (0.03 ) $ 0.18 (1)Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company. For a reconciliation of Adjusted EBITDA from continuing operations to net income (the most comparable measure under GAAP), see “Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)” below. Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss) The following tables reflect a reconciliation of Adjusted EBITDA from continuing operations to net income (loss) from continuing operations, as presented by the Company: For The Three Months Ended June 30, 2026 (in thousands of U.S. dollars) Cannabis Other Corporate Total Net income (loss) from continuing operations $ 8,603 $ 1,734 $ (3,192 ) $ 7,144 Add: Amortization and depreciation 3,483 777 19 4,279 Foreign currency exchange (gain) loss (60 ) 43 406 389 Interest expense (income), net 35 207 (108 ) 134 Provision for income taxes 3,216 46 — 3,262 Share-based compensation 56 — 237 293 Deferred financing fees 67 — — 67 Loss on disposal of assets — (31 ) — (31 ) Adjustments attributable to non-controlling interest (127 ) — — (127 ) Adjusted EBITDA from continuing operations (1) 15,273 2,776 (2,638 ) 15,411 For The Three Months Ended June 30, 2025 (in thousands of U.S. dollars) Cannabis Other Corporate Total Net income (loss) from continuing operations $ 7,098 $ 4,495 $ (1,390 ) $ 10,203 Add: Amortization and depreciation 3,117 1,913 38 5,068 Foreign currency exchange gain (84 ) (130 ) (1,529 ) (1,743 ) Interest expense (income), net 316 414 (25 ) 705 Provision for (recovery of) income taxes 2,387 135 (19 ) 2,503 Share-based compensation 37 6 80 123 Deferred financing fee 47 — — 47 Other impairments 217 — — Adjustments attributable to non-controlling interest (12 ) — — (12 ) Adjusted EBITDA from continuing operations (1) 13,123 6,833 (2,845 ) 17,111 For The Six Months Ended June 30, 2026 (in thousands of U.S. dollars) Cannabis Other Corporate Total Net income (loss) from continuing operations $ 13,383 $ 595 $ (3,916 ) $ 10,062 Add: — — — — Amortization and depreciation 6,985 1,554 43 8,582 Foreign currency exchange loss 15 123 799 937 Interest expense (income), net 64 383 (388 ) 59 Provision for income taxes 4,801 129 — 4,930 Share-based compensation 128 — 541 669 Deferred financing fees 139 — — 139 Loss (gain) on disposal of assets 118 (31 ) — 87 Adjustments attributable to non-controlling interest (154 ) — — (154 ) Adjusted EBITDA from continuing operations (1) 25,479 2,753 (2,921 ) 25,311 For The Six Months Ended June 30, 2025 (in thousands of U.S. dollars) Cannabis Other Corporate Total Net income (loss) from continuing operations $ 9,946 $ 2,066 $ (3,509 ) $ 8,503 Add: — — — — Amortization and depreciation 6,055 2,273 82 8,410 Foreign currency exchange (gain) loss (135 ) (82 ) (1,544 ) (1,761 ) Interest expense (income), net 457 924 (49 ) 1,332 Provision for income taxes 3,282 204 — 3,486 Share-based compensation 85 19 164 268 Other Impairments 47 — — 47 Goodwill and intangible impairments (1) 217 — — 217 Adjustments attributable to non-controlling interest 58 — — 58 Adjusted EBITDA from continuing operations (1) 20,012 5,404 (4,856 ) 20,560 (1)Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company. This press release is intended to be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, which will be filed with the Securities and Exchange Commission and will be available at www.sec.gov, and will also be filed in Canada on SEDAR+ (www.sedarplus.ca). In addition, quarterly financial reports can be found on the Village Farms website under Financial Reports (https://villagefarms.com/financial-reports/) within the Investors section. Cautionary Statement Regarding Forward-Looking Information As used in this Press Release, the terms “Village Farms”, “Village Farms International”, the “Company”, “we”, “us”, “our” and similar references refer to Village Farms International, Inc. and our consolidated subsidiaries, and the term “Common Shares” refers to our common shares, no par value. Our financial information is presented in U.S. dollars and all references in this Press Release to “$” means U.S. dollars and all references to “C$” means Canadian dollars. This Press Release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is subject to the safe harbor created by those sections. This Press Release also contains "forward-looking information" within the meaning of applicable Canadian securities laws. We refer to such forward-looking statements and forward-looking information collectively as "forward-looking statements". Forward-looking statements may relate to the Company's future outlook or financial position and anticipated events or results and may include statements regarding the financial position, business strategy, budgets, expansion plans, litigation, projected production, projected costs, capital expenditures, financial results, tariffs, taxes, plans and objectives of or involving the Company. Particularly, statements regarding future results, performance, achievements, prospects or opportunities for the Company, the greenhouse vegetable or produce industry, the cannabis industry and market and our energy segment are forward-looking statements. In some cases, forward-looking information can be identified by such terms as "can", "outlook", "may", "might", "will", "could", "should", "would", "occur", "expect", "plan", "anticipate", "believe", "intend", "try", "estimate", "predict", "potential", "continue", "likely", "schedule", "objectives", “position” or the negative or grammatical variation thereof or other similar expressions concerning matters that are not historical facts. The forward-looking statements in this Press Release are subject to risks that may include, but are not limited to: our limited operating history in the cannabis and cannabinoids industry, including that of Pure Sunfarms, Corp. (“Pure Sunfarms”), Rose LifeScience Inc. (“Rose” or “Rose LifeScience”), Balanced Health Botanicals, LLC (“Balanced Health”), and Village Farms International B.V. (“VF International”); the limited operational history of the Delta RNG Project in our energy segment and VF International; the legal status of the cannabis business of Pure Sunfarms, Rose and VF International and the hemp business of Balanced Health and uncertainty regarding the legality and regulatory status of cannabis and cannabinoid (CBD) products in the United States; risks relating to the implementation and enforcement of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026 which mat materially and adversely affect our CBD business in the United States; risks relating to the operation of our collaboration with Verdexa Holdings; risks relating to obtaining additional financing on acceptable terms, including our dependence upon credit facilities and dilutive transactions; potential difficulties in achieving and/or maintaining profitability; variability of product pricing; risks inherent in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses; our market position and competitive position; our ability to leverage current business relationships for future business involving hemp and cannabinoids; the ability of Pure Sunfarms and Rose to cultivate and distribute cannabis in Canada as well as exports; risks related to the start-up of international production at our Netherlands operations under VF International; existing and new governmental regulations, including risks related to regulatory compliance and regarding obtaining and maintaining licenses required under the Cannabis Act (Canada), the Criminal Code and other Acts, S.C. 2018, C. 16 (Canada) for our Canadian operational facilities, and changes in our regulatory requirements; legal and operational risks relating to expected conversion of our greenhouses to cannabis production in Canada and in the United States; risks related to rules and regulations at the U.S. Federal (Food and Drug Administration and United States Department of Agriculture), state and municipal levels with respect to produce and hemp, cannabidiol-based products commercialization; retail consolidation, technological advances and other forms of competition; transportation disruptions; product liability and other potential litigation; retention of key executives; labor issues; uninsured and underinsured losses; vulnerability to rising energy costs; inflationary effects on costs of cultivation and transportation; recessionary effects on demand of our products; environmental, health and safety risks, foreign exchange exposure, risks associated with cross-border trade and the potential for tariffs and other trade restrictions; difficulties in managing our growth; restrictive covenants under our credit facilities; natural catastrophes; elevated interest rates; and tax risks. The Company has based these forward-looking statements on factors and assumptions about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Although the forward-looking statements contained in this Press Release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond the Company's control, which may cause the Company's or the industry's actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, the factors contained in the Company's filings with securities regulators, including this Press Release and the Company’s most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking statements made in this Press Release relate only to events or information as of the date on which the statements are made in this Press Release. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Village Farms International, Inc. Condensed Consolidated Statements of Financial Position (In thousands of United States dollars, except share data) (Unaudited) June 30, 2026 December 31, 2025 ASSETS Current assets Cash and cash equivalents $ 72,931 $ 81,189 Restricted cash — 5,063 Trade receivables, net 32,406 23,151 Inventories, net 46,669 41,519 Other receivables 1,397 324 Prepaid expenses and deposits 6,923 3,191 Total current assets 160,326 154,437 Non-current assets Property, plant and equipment, net 190,058 185,712 Investments 6,276 6,276 Goodwill 42,775 44,365 Intangibles, net 21,137 23,647 Deferred tax asset 564 694 Right-of-use assets 5,388 4,066 Other assets 1,943 3,899 Total assets $ 428,467 $ 423,096 LIABILITIES Current liabilities Trade payables $ 17,587 $ 15,747 Current maturities of long-term debt 5,249 4,885 Accrued sales taxes 7,068 8,695 Accrued liabilities 16,699 13,960 Lease liabilities - current 1,169 1,198 Income tax payable — 12,151 Other current liabilities 2,836 1,950 Total current liabilities 50,608 58,586 Non-current liabilities Long-term debt 34,713 28,769 Deferred tax liability 17,329 18,494 Lease liabilities - non-current 5,058 3,855 Other non-current liabilities 2,111 3,330 Total liabilities 109,819 113,034 MEZZANINE EQUITY Redeemable non-controlling interest 6,447 10,164 SHAREHOLDERS’ EQUITY Common shares, no par value per share - unlimited shares authorized;121,844,464 shares issued and outstanding at June 30, 2026 and 115,722,312 common shares issued and outstanding at December 31, 2025. 407,031 392,380 Additional paid in capital 24,931 29,374 Accumulated other comprehensive loss (17,248 ) (9,281 ) Retained earnings (102,513 ) (112,575 ) Total shareholders’ equity 312,201 299,898 Total liabilities, mezzanine equity and shareholders’ equity $ 428,467 $ 423,096 Village Farms International, Inc. Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (In thousands of United States dollars, except per share data) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Sales $ 63,977 $ 59,899 $ 114,215 $ 99,579 Cost of sales (34,004 ) (37,557 ) (63,256 ) (63,057 ) Gross profit 29,973 22,342 50,959 36,522 Selling, general and administrative expenses (18,811 ) (15,411 ) (34,753 ) (30,030 ) Interest expense (477 ) (814 ) (1,000 ) (1,516 ) Interest income 343 109 951 184 Foreign exchange (loss) gain (597 ) 1,792 (1,145 ) 1,708 Other income (loss) 24 4,430 (159 ) 4,451 Income before taxes and equity method investment income 10,455 12,448 14,853 11,319 Provision for income taxes (3,262 ) (2,503 ) (4,930 ) (3,486 ) Equity method investment income, net of tax — — — — Income from continuing operations 7,193 9,945 9,923 7,833 Income from discontinued operations, net of tax — 16,294 — 11,291 Income including non-controlling interests 7,193 26,239 9,923 19,124 Less: net (income) loss attributable to non-controlling interests, net of tax (48 ) 258 139 670 Net income attributable to Village Farms International, Inc. shareholders $ 7,145 $ 26,497 $ 10,062 $ 19,794 Basic income per share attributable to Village Farms International, Inc. shareholders from: Continuing operations $ 0.06 $ 0.09 $ 0.09 $ 0.08 Discontinued operations - 0.15 - 0.10 Basic income per share attributable to Village Farms International, Inc. shareholders $ 0.06 $ 0.24 $ 0.09 $ 0.18 Diluted income per share attributable to Village Farms International, Inc. shareholders from: Con